UNSPSC 51102900: Combination antimalarials

This classification denotes combination drugs that treat a protozoan disease caused in humans by four species of the plasmodium genus: plasmodium falciparum; plasmodium vivax; plasmodium ovale; and plasmodium malariae; and transmitted by the bite of an infected female mosquito of the genus anopheles, a disease called malaria, and hence the term ANTIMALARIALS. Typical combination antimalarial constituents are artemether, atovaquone, chloroquine, and pyrimethamine.

UNSPSC 51102900 Combination antimalarials is a Class code, but the recent state and local opportunities tagged under it show minimal alignment with antimalarial pharmaceuticals. Instead, the code has captured a diverse set of medical and pharmaceutical procurements including emergency response supplies, naloxone distribution systems, direct-to-manufacturer pharmacy initiatives, and generic multistate pharmaceutical contracting. State and local governments soliciting under this code include county health departments (Seminole County, Florida), city fire departments (City of Tampa), state health commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The actual work being bought ranges from first-aid and emergency medical consumables for rescue operations to bulk generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to state and local government facilities.

Recent activity spans Florida, Texas, Minnesota, and Oregon through cooperative arrangements. Representative solicitations include the City of Tampa's IFB for medical and first aid supplies (169 line items of respiratory equipment, cardiac monitoring devices, bandaging materials, and consumables) with a $700,000 estimated contract amount and a sheltered-market 5% small local business enterprise discount; Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023); Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, with contract effectiveness July 1, 2026). The mismatch between the code's nominal scope (antimalarials) and recent solicitations indicates either broad tagging practices in state procurement systems or that the code functions as a catch-all for pharmaceutical and medical supply purchases beyond its technical definition.